Smith+Nephew

Smith+Nephew is a global portfolio medical technology company that designs and manufactures technology for the repair, regeneration and replacement of soft and hard tissue. Founded in 1856, the company traces its origins to a pharmacy in Hull, England, and today employs more than 18,000 people and operates in over 100 countries. It is publicly listed on the London Stock Exchange, where it is a FTSE 100 constituent, and on the New York Stock Exchange.

The business is organised into three global units: Orthopaedics; Sports Medicine + ENT; and Advanced Wound Management. Its technical work spans orthopaedics, sports medicine, ear, nose and throat, advanced wound management, robotics-assisted surgery, negative pressure wound therapy, bioinductive implant technology and medical device design and manufacturing. Products include the PICO negative pressure wound therapy system, the CORI Surgical System for robotics-assisted surgery, and the REGENETEN Bioinductive Implant for tissue repair and regeneration.

Smith+Nephew serves millions of patients annually and works with healthcare professionals on reducing the human and economic cost of wounds; its athletes programme includes work with UFC fighter Tom Aspinall, who is recovering from career-threatening injuries. The company states its mission as existing "to restore people's bodies and their self-belief by using technology to take the limits off living".